

Rebooting The Body's Defense: Innovations in Immunotherapy Treatment

Maria NAZIR

Aansa TAHREEM

Fatima SAGHEER

Rumaisa NAWAL

Shafeeq ur REHMAN

Muhammad SAFDAR

Mehmet OZASLAN

1. Introduction

The immune system can be described as the combination of our internal, molecular, cellular, and other processes to suit an entire defense mechanism we need during the fight with countless external agents (Paul, 2012). This is also the best way of keeping us healthy. It is very effective in that it has no way for the pathogens i.e. viruses and bacteria to use by is impossible for them to adapt to the environment allowing our body to fight the infection. Two different kinds of activities involve the use of a foreigner's forces to drive foreigners away from our territory, while the other type is the locating and damaging of erratic cells such as those that can lead to cancer. Nevertheless, the immune system may have problems with this war on the enemy when they cross over the borders of the defensive system when autoimmunity causes malfunction of the immune system against its healthy part, and when cancer becomes a sales squad of cells that fights against the rest of the body parts. Therapy is obtained from Immunology, and medical researchers are in extremely busy work. Immunotherapy will make a great revolution in medicine, pushing the body's immune system (as shown in Table 1) against those invaders (Khan & Lopez, 2023).

Immunotherapy which was a concept now become a fact of life and is being practiced, it is giving way to a new face of cancer, and autoimmune diseases, and, may even prove useful in infectious disease treatment. This chapter will take us back in time, to where the foundations of immunotherapies were built, what information this knowledge is based on, and into the front-line technology that changes the lives of thousands of patients around the globe. That a thought that was only an idea back then has become today's clinical reality is great evidence for scientific development and life expectancy prolonging. The earliest immunotherapies generally employed the potency of antibodies, which are the proteins that are highly specific and only distinguish the foreign substances or dangerous cells, and after identifying them, label them for destruction by the immune system (Sompayrac, 2022). In addition to viral diseases like measles, smallpox, and polio that the vaccines held responsible for the decline in level of morbidity and mortality, the human immune system also serves as a teacher that nourishes it. However, the original versions had the great power of symbol and emotion lived differently by different people.

Table 1: Milestones in Immunotherapy Development

Decade	Milestone	Significance	Reference
1800s	Coley's Toxins	Concept of immunotherapy in the early stages	(Ventola, 2017)
1950s	Tumor antigens & interferons	The ability of the immune system to fight cancer	(Williams & Williams, 2019)
1970s	BCG vaccine for bladder cancer	First approved immunotherapy	(Cole et al., 2023)
1980s	Monoclonal antibodies	Targeted therapy revolution	(Falzone et al., 2018)
1990s	IL-2 for metastatic kidney cancer	First cytokine therapy	(FIGLIN, 1999)
2000s	Dendritic cell vaccines & sipuleucel-T	Personalized immunotherapy	(Srivastava et al., 2019)
2010s	Checkpoint inhibitors & CAR-T therapy	Transformative cancer treatment	(Nash et al., 2021)
2020s	Continued advancements	Refining and exploring new therapies	(Neukart, 2024)

The real-world understanding of molecular biology's latest achievements and a deeper look at the main principles of the immune system work were kind of groundwork for the presently progressing immunotherapy. Through the studies, scientists are now more educated about the immune system at the deep level and its ability to serve its purpose well. The shroud of immunological suppression is another line of defense mechanism with the immune checkpoint which ensures that the immune system never gets overstimulated and seriously harms the tissue regardless of a healthy body's development. However, these cancerous cells can do such a thing that evades the immune detection mechanism. Therefore, they are not getting killed (Bhatia & Kumar, 2014). The same strategy – the immune checkpoint inhibitors, which are already in use, were specifically designed to counterbalance these signaling molecules that restrain the immune responses. That is how the immune system can foster its ability to cope with and defeat cancer cells. The recent innovation of monoclonal antibody therapy can be seen as a result of such practice of building molecules, which are designed and specified with a high safety of only binding of the cancerous cell molecules or components of the immune oscillatory system. These actions might favor the aggregation of immune cells at the malignant sites, although the oscillation of the immune system might be altered as well (Silva et al., 2023).

One cell therapy that has facilitated these researchers to dream this way is CAR-T cell therapy. It entails a form of therapy by which the T cells (a type of white blood cells) of a patient are genetically engineered and multiplied in a laboratory thereby resulting in an army of cells that can destroy cancer; this regime of therapy has them empowered with antibody-like receptors (Suryaprakash et al., 2023). CAR-T cells have the unique property of being able to eliminate the cancer cells and then keep monitoring them permanently. This eliminates the problem of recurrence of cancer as the cells can heal themselves in the case of relapse. Throughout cancer therapy, it is widely known that the biggest endeavors and achievements were in immunotherapy, however, the borders of this field are not set and they span beyond oncology. In contrast with the early days when there were no vaccines against cancer, the Smart vaccines of today are being designed in individualized ways - using fragments of a patient's tumor or targeting multiple cancer antigens. On the other hand, the exploitation of oncolytic viruses the case of which can selectively wipe out cancer cells utilizing stimulating anticancer immune responses is a promising pathway for cancer treatment (Rahman & McFadden, 2021).

2. Understanding the Immune System

During the body's struggle with the destructive agents, the human complex system of death, as well as reconstruction recreating processes, become especially the human immune system. This intricate network, which is both the outer buster and the inner doctor, guards us against a broad range of things from the outside and the inside that can potentially harm us. These include viruses, bacteria, and intestinal parasites as well as illnesses like tumors within us. For beginners, fasten your seatbelts and prepare to discover the fundamentals of this powerful force. The immune system broadly consists of two interconnected branches: the physiologic state of rest and the state of transition (Roy & Bagchi, 2020). The immune system has two pillars innate and adaptive immunity. the original immunity as well, which is responsible for the instant and non-specific reaction. This is a rapid-response group of cells that when deployed activate a huge passage of macrophages and neutrophils over the invader to surround them and then engulf them, additionally, they release signals that induce inflammation which is a highly effective anti-microbial response (Pallister & Watson, 2010). It is the natural course; the specialized adaptive immune system earns more time as a sensor (of the attack) but at the same time, the same system becomes supremely specialized and highly effective as consumers of the disease-causing factors that impose the attack on the organism. It is necessary to consider lymphocytes which are two different types of cells, such as T cells and B cells, that are part of an adaptive system. The T-cells are known as the cellular base for the immune reaction, they carry the role of killing the infected and cancerous cells that must be eliminated from the body to let the immune response function efficiently (Kartikasari et al., 2019). Nevertheless, by comparison, the B cells are the predominant cell type in the humoral immunity and specific antibody formation (as shown in Figure 1). This procedure is centrally based on the production of highly selective proteins whose mechanisms are of paramount importance. It is also worth noting that these proteins not only have a high affinity to toxic pathogens but are also able to detoxify them, alongside the subsequent processing and further utilization of the debris by the macrophages (Brüne et al., 2013). On the one hand, the immunological system needs foolproof strategies for perceiving threats but on the now, such systems also have to be well-regulated to avoid the self-wrecking of healthy tissues. Another aspect is that the class of immune checkpoints never allows the immune system to be in an excessive state. The immunity process for the body is being lost therefore the body's self can be attacked by the immunity. Contrary to this, some cancer cells can dodge the interception and therefore do not come under the immune checkpoint regulation.




Figure 1. Understanding the Immunity

The labors aimed at the increase of knowledge from the cellular and molecular natural environment of the immune system are proof of the progression of immunotherapy. Scientists have lastly revealed a new immune cell type that mainly functions in differentiating development and suppression of the activation phase, as very important tasks. The most appropriate scheme is regulatory T cells (Treg) which operate as suppressors of immune responses and hence are good candidates in mitigating autoimmune illnesses and recipient organ transplants (Romano, 2015). The possibility that the trillions of microbes constituting the microbiome which are the hosts of the human body, may be the essence of innately immune system function, and eventually be a primary force in the child development stage has been revealed. The gut microbes play these noteworthy signals that bring the balanced responses from the immunological side to industriously produce the best immune responses. The slight shift in the differing proportions of the microbiome of an individual may cause a rise in psychiatric disorders and autoimmune diseases (Muszer et al., 2015).

The immune system is not a static object, rather this is a dynamic base on which many reactions take place during our life. The immune system responds effectively against pathogens when the balance is maintained. Genetics aspects are the factors that influence the emergence of some illnesses and reviving the immunity system (Lazar et al., 2018). Our body and microbes live alongside us in intimate symbiotic relationships, when we encounter stress, we modify our diet, along with our exposure to the organisms belonging to this environment; these factors all affect the immune system.

3. Evolution of Immunotherapy

The fact that manipulating the way the immune system works to combat disease has been around as far back as several hundred years ago. The earliest immunotherapies that were uncovered were with these pathogenic agents directly infused to generate immunity on an automatic base. This period saw the beginning of several very important inventions, particularly the vaccine against smallpox, found by Edward Jenner in the 18th century. This is a widely recognized milestone, which brought a new era in medicine, as well as a significant step in that direction (Wu et al., 2019). Furthermore, genetics got new advancements by recognizing antibodies as a new phenomenon (as shown in Table 2). As the exact method of this compound to treat different diseases especially, of course, was known since the late 1800s and is mentioned in the literature as well, it can be said that the moment of a tremendous jump in production was organized in the 1970s when the culture of monoclonal antibodies (specific antibodies developed from single cells) was finally synthesized which was achieved. As of today, the first monoclonal antibody licensing for oncology therapies happened in 1997 year (Lu et al., 2020). The second therapy majorly was monoclonal antibody treatments that were a cornerstone of cancer treatment for many types including autoimmune conditions like rheumatoid arthritis and Crohn's disease (Flevaris & Kontoravdi, 2022).

Table 2: Evolution of Immunotherapy

Period	Key Advancements	Reference
The late 1800s	Coley's Toxins are bacterial toxins used to stimulate tumors.	(Löwy, 2003)
The early 1900s	BCG vaccine was initially developed for tuberculosis treatment and later found to be effective for treating bladder cancer as well.	(Ikryannikova et al., 2023)
Mid 1900s	Recognition of tumor antigens by the immune system is facilitated by interferons.	(Tian et al., 2022)
Late 1900s	Therapy that is targeted and enhanced using monoclonal antibodies and IL-2.	(Helmy et al., 2013)
The early 2000s	Personalized therapy with dendritic cell vaccines and sipuleucel-T.	(Mukherjee et al., 2022)
2010s	Checkpoint inhibitors & CAR-T therapy have completely transformed the way we treat patients.	(Zhang et al., 2023)
Future	Ongoing developments in the field of combination and personalized therapies.	(Dey et al., 2023)

Cancer vaccination is not a modern invention but is a central theme without tangible results from millennia ago. Elimination treatment procedures have been the major choice in cancer treatment for a long time by targeting some tumor cells or tumor antigens to cue the immune system for cancer marker recognition. Nevertheless, they raised the theoretical vision, but the vaccine in practical applications did not provide us with highly durable and predictable clinical outcomes. The achievements in the field of cancer vaccination design are much more limited compared to expected because of the immunoreactive ability problem. However, the targets for immunogenicity are identified more accurately, and the immune evasion mechanisms and delivery systems for the tumors are fully understood. New stages for cancer vaccines are opened up (Fan et al., 2023). Such an important move was the discovery of immune checkpoints in the 1990s as well as the advent of immuno-oncology (Wilky, 2019). Yet the world of scientific research cannot stand eternally at a halt – James Allison and Tasuku Honjo found CTLA-4 and PD-1 to be the major two "brake pads" that may lead to uncontrolled immune responses. The process of this research led to another discovery that is commonly called immune checkpoint inhibitors a kind of medicine that seemed to be a real solution to the cancer disease problem (Dobosz & Dzieciatkowski, 2019). The immune checkpoint inhibitors, for example, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have been accounted for being widely used in the treatment of cancer patients over the last few years. They exert their immune suppression activity by blocking the signaling pathways employed by malignant cells for their benefit; thus, enabling the immune system to completely unleash its potential for a total annihilation of tumor cells.

The past several years have witnessed new cell therapies establishing themselves as an immunotherapy field sub-specialty. Secondly, destitution in this cancer treatment was a telling signification of how the transplanting of immunity cells can be a great weapon in combatting this disease. CRISPR-Cas9 is a modern CRISPR technology capable of removing genetic material or inserting it in a target cell (Gupta et al., 2019), such as a T cell or any kind of cancer cell, allowing it to fight cancer cells and perform anti-cancer activities more effectively. Advancement attained in the field of CAR-T cell therapy based on breakthroughs seen in leukemia and lymphoma has resulted in FDA approval of CAR-T cells as a treatment in many blood cancer recipes, thereby opening a new path for adding the cure to the immunotherapy armory (Shouval et al., 2022). Another great area wherein advanced research should be undertaken is the oncolytic viruses applied as a treatment. These arrays of infections can specifically target and destroy malignant cells that block cancer spread. Likewise, the anti-tumor activity of a virus does not only include its direct toxicity to tumor cells but also facilitates the patient's immune response, implying that the oncolytic virus

is advantageous in terms of both mechanisms (Raja et al., 2018).

Although there are currently problems with immunotherapy delivery, which are mainly connected with personalized treatment, scientists continue working on overcoming them (Raja et al., 2018). Scientists are enlightening the community after depicting the relationship between cancer characteristics, the implantation of the composition of immune systems, and varieties of the microbiome of a particular patient, and these data will be useful in making an effective selection of a particular patient for a specific treatment. This special kind of treatment program can bring the best result out of it and will make sure that unnecessary side effects are avoided. This makes individualized immunotherapy more targeted to the disease-specific patient and proteins (Krzyszczuk et al., 2018).

4. Immune Checkpoint Inhibitors

Immune checkpoints are an intrinsic immunity system regulatory system that prevents the immune system from generating a rampage in which harmful effects to the body's organs are their results. They function as protective units and stop the needless launch of pro-inflammatory cytokines, which over time could produce autoimmune diseases (Manik & Singh, 2022). On the other hand, the human immunosystem has also developed some natural barriers to protect the body against cancer including cells like immune cells and antibodies. While this is the case, pathologists tell us that cancer cells are in some ways super smart and can take advantage of the system that our immune cells try to fight with them. It is as if the cancer cells disguise themselves so cleverly that the immune system cannot identify and destroy them, resulting in cancer cells multiplying and spreading to other organs (Šmardová, 2024). Immunoadjuvants have brought a revolution in the treatment of cancer by, on the one side, inducing cell death and on the other side exposing the cancer cells to the immune system. The two essential checkpoint pathways histronic proteins CTLA-4 and PD-1/PD-L1, are located in several immune cells. At present, checkpoint blockade drugs have become monoclonal antibodies that can be considered as immunotherapies. These checkpoint inhibitors will oppose the checkpoint brake and enable constant signaling. Hence, those therapies will hold heat, and at that time, the T cell, which is one of the major cell-mediated arms of the immune system, (as shown in Figure 2) can detect and kill particular cancer cells that were marked (Kumar et al., 2021).

Some clinical trials showed some cancers as very responsive to immunotherapy. When these cancers lose control over immunity, they are highly sensitive to checkpoint inhibitors. Characterized by the highest rate of response are melanomas, lung cancers of certain types, head and neck cancers, renal cancer as well liver carcinomas among others that have withstood several years of immunotherapy reliant on checkpoint inhibitors (Bridge et al., 2018). Analyzing checkpoint immunotherapy drugs that specifically work against cancers has already gained its mark as a weapon against cancer treatments. The FDA authorizes an expanding number of cancers including melanoma, NSCLC, and kidney cancer so that immune checkpoint inhibitors can be activated against the aforementioned cancers. Later, the PD-1 / PD-L1 pathway was found to be the other next target, allowing ipilimumab (anti-CTLA-4) to be approved in 2011 (Chae et al., 2018). Thereafter the development of other drugs also took place including nivolumab, pembrolizumab, atezolizumab, and others.




Figure 2. Immune Checkpoint Inhibitors in T-Cell

Though this medicine may not one hundred percent duplicate all vitalities provided by nature, it will still provide so many advantages that can never be overlooked. It is vital to stress that not all cancer cases can be cured utilizing immune checkpoint inhibitors and that some are the ones with high response levels, some the others with low response levels. Identifying specific patients who are most susceptible to certain checkpoint inhibitors and the exact role of immunotherapy is no doubt the aim of the research (Wojtukiewicz et al., 2021). The key lesson from this experience has been to start to use a thinking process that is critical and more independent. On top of that, I have learned to manage myself outside the dependence on others as well as how to take ownership of my health care. Also, biomarkers such as PD-L1 expression level and tumor cell mutation status give a clue as to when a patient is most likely to benefit from checkpoint blockade treatment (Fujii et al., 2018). Anti-immune checkpoints crazy the brakes of the immune system, which is supposed to preserve and promote good health in the body. As a side effect of this drug mode of operation, there are some cases of immune-induced illnesses. Meanwhile, organ inflammations such as skin and gut, that require close monitoring, introducing other immune-suppressive therapy are also brought in for unforeseen events (Rapoport et al., 2017). At the moment, scientists are working on a scale-up process of checkpoint inhibitor production which is based on the entire cells and cell lines that are specially engineered for this. Checkpoint inhibitors are the other approach where an array of these inhibitors is employed in certain combinations or just a single one of them could be administered. A patient with one cancer and another will especially benefit a therapy with a CTLA-4 substance and a PD-1 substance while other people can show lower effectiveness from such treatment to a CTLA-4 treatment separately. Finally, a demand for more clinical studies into combining immunotherapy with conventional treatment modes like chemotherapy, radiology, and targeted therapies is another key area with some thrilling studies about new and effective methods of treatment (Kamrani et al., 2023).

5. CAR-T Cell Therapy

Chimeric antigen receptor gene transfer therapy which is also known as CAR T cell therapy is a game changer in the field of cancer immunotherapy and this case, the cells are redesigned to ensure that patients are no longer bedridden by this deadly disease but that they are each other and all the resources they need to fight cancer. The output confirms the point that CAR-T cell therapy is a variable that can be used and redesigned (as shown in Figure 3) for the fight against the disease (Ahmed, 2021).




Figure 3. Overview of CAR-T Cell Therapy

The T cells, which are a type of white blood cells, are the immunity combatants in our body and are very important in our immunity system. They will mark out and obliterate both them and the transformed health cells. T cells can target these cells, which have unfettered those cells that betray, but cancer cells still suppress these T cells, which enhances these cells' ability to proliferate. CAR-T cell therapy blazes novel pathways for the editing of T cells to enhance their ability to not only recognize but also eradicate even the most wicked cancer cells as targeted and persistent as these cells (Han, 2016). This approach entails “arming” patients' T cells which are the body's defenders by introducing CARs into them such that the T cells can function as though they are customized fighters eliminating cancer cells this way (Ayala, 2016). On the very, first step, collecting the patient's T cells by taking out his blood with the standard method of blood donation. Cells from the blood are drawn in the lab and through genetic engineering, the DNA molecules within them are redone to provide this specific receptor molecule of chimeric antigen receptor (CAR). The CAR is comprised of the antibody and T-cell receptors since they are the trigger mediators. The role of the antigen binding potential of CAR is to properly couple the CAR to an antigen (complementary protein) on the surface of the cancer cell, thereby giving precision to a harpoon on the carrier which in turn binds the cancer cell to the CAR-T cell. Finally, when the tumor cell sticks to the CAR receptor, a certain cell subset of the innate and adaptive immunity will recognize them as targets (Willcox et al., 2020). These CAR T-cells are then graded and placed in the laboratory to enhance their replication, since they multiply exponentially in can be taken in millions. Therefore, when the CAR-T cells are decided as ready, they enter through the bloodstream to join the patients. Indeed, this cell transfer can be in a way regarded as an internal and living drug. Following on, the CAR-T cells would be the ones now seeking and destructing the cancer cells having installed their antigen distinctly. Rather chemotherapy drugs are more approaches to treat cancer that are only in use single time, the CAR-T cells can multiply inside the patient, which provides the opportunity to achieve a long period at which active cancer can be fought (Safarzadeh Kozani et al., 2022).

Although the CAR-T cell technology mainly focuses on blood-conditioned cancers (leukemia or lymphoma), (as shown in Figure 4) it is the early clinical trials that indicate positive responses. This therapy is really useful in case of recurrence or when the patients attend other treatment modes and response is poor, especially for those whose aggressiveness doesn't respond to other measures. Here CAR-T gives only hope for remission and chances for cure. Over FDA-approved cell therapy drugs for the indication of treating cancers as well (Mitra et al., 2023). Despite the benefits CAR-T therapy provides by being a very strong technique it also comes with its risks and dangers. Cytokine Release Syndrome (CRS), A broad-spectrum systemic inflammation effect that arises from a rapid expansion of CAR-T cells, is a very severe and, sometimes, even fatal

complication (Cobb & Lee, 2021). Realizing CRS may lead to flu-like illness where the body can attain a fever at times. At times, stressors may become more severe, potentially leading to a triad of disorders. Organ harm can be a consequence. Neuronal toxicity is said to be one possible complication that can be experienced by patients after the CAR-T cell treatment, the severity of the side effects ranges from minor symptoms like seizures and confusion to serious conditions. On a more optimistic note, is the fact that researchers have devised some practical ways in which the side effects of the rigid protocol can be managed. This has led to gradual progress in the safety of CAR-T therapy (Cauchon et al., 2019).




Figure 4. Process of CAR-T Cell Therapy

The therapy CAR-T is a promising innovation with a growing branch that implies the better carrier of this treatment is getting closer and closer. Given the already successful track record as far as blood cancer treatment, the scientists continue to work on tackling this by offering alternative ways of treating solid tumors. By contrast, solid tumors comprise considerably more multifarious problems than liquids due to the cells of the CAR-Ts being near solid masses and the deformation of the latter (Clark et al., 2019). Investigators search for ways how to create an advanced generation of CAR-T cells with higher potency and avoid related problems by using this approach for those types of cancer that are not very responsive now. Additionally, to the investigative domains for future research include that of genetically engineered, normal donor-derived CAR-T cells in substitution of the patient's cells. On the other hand, this means the patients don't have to incur the high cost associated with an expensive customization process, so the availability of mass-produced products can have a positive effect due to easier treatment access. Moreover, CRISPR techniques among other molecular biology tools could be used for the acceleration of the process allowing the level of changes to another level (Nidhi et al., 2021).

6. Monoclonal Antibody Therapy

On the whole, CD19-specific chimeric antigen receptor (CAR) T cell therapy stands at the boundary of immunotherapy, being both a scissor and a stitcher to disarm and rearm the patient's cells into anticancer machine guns. It means a novel epoch devoted to custom-tailored medicine

that employs patients' reservoirs those powers that stabilize their bodies (as shown in Figure 5). T cells provide cellular bases for immune response by attacking and disabling the cells affected by the harmful intruder. But on the other hand, cancer cells retain such intrinsic powers for evading immune detection. In comparison to CAR-T cell therapy, this kind of treatment is not powerful enough to do over the immunosuppressive state that is often associated with cancer cells (Safarzadeh Kozani et al., 2022). Generally, the process starts with a T cell provided from one of the patient's blood donation kinds which is conducted as irregularly as possible. In the laboratory, the CAR T cells take a new gene which includes it within a chimeric receptor as long as CAR. In addition to it, this certain molecule has one part that appears as an antibody and attaches itself to the antigen on the surface of the cancer cells. This specific targeting portion has been imprinted with engineered components that come from T cell receptors, which, when these T cell receptors are attached to cancerous cells, may increase the destruction power of the cell towards the cancer cell (Liu et al., 2020).




Figure 5. Monoclonal Antibody Productions

These CAR-T Cells are then expanded to millions in the lab in weeks instead of taking months to reach the clinical stage of treatment. This is how the conjugated antibodies, if present in a person's blood, resemble a "living drug" that selectively searches and eliminates cancer cells that bear the target antigen (Afsahi, 2023). Unlike traditional chemotherapy which has intermittent on-and-off effects, the CAR-T cells are free of such constraints, thus having the ability to live the recipients and keep tabs on possible cancer recurrence. While at present CAR-T therapy has proved to be very promising in the treatment of blood cancers, especially leukemias, and lymphoma, it has not yet been able to bring encouraging results in the treatment of solid tumors (as shown in Figure 6). Here it has acted as a means to make patients who undergo successful therapies take it easy as well and issues with efficacy in other cancer treatment procedures disappear. These FDA-certified, multi-disciplinary treatment trials can be accounted for as Phase I and Phase II clinical trials approved by the FDA, and the statistics show a significant effect of the treatment on blood cancers (Armstrong, 2015).




Figure 6. Monoclonal Antibody Binding to a Target Protein on a Cancer Cell

While the CAR-T breakthrough treatment seems to be a game-changing therapy, the approach comes with its weaknesses which should be addressed. Cytokine release syndrome (CRS) or a “systemic inflammatory reaction produced by very rapid CAR-T cell activity may be moderate as influenza-like disease or worse as multi-organ damage. The issues related to toxic signage like salt anions that may lead to confusion or epilepsy are highlighted in the sentence that follows. However, this can be summed up by the use of management strategies, made possible to restore patient safety to the highest possible level. This can be made through the gathering of information from patients, doctors, and the manufacturer of the drug. This can be followed by extensive research on the adverse effects of such therapy (Garrison Jr et al., 2007). While CAR-T cell therapy shows promising results, we are enjoying remarkable achievements. Overall, without these complex diverse microenvironments of solid tumors, there is always one of the major issues with infiltrating CAR-T cells. The researchers aim to deliver the novel CAR-T cells to the next generation with the ability to tackle the obstacles and thus reach the intended mutated cells (Kapoor-Narula & Lenka, 2022).

7. Cancer Vaccines and Oncolytic Viruses

The vaccine for cancer and oncolytic virus is a new and emerging technology serum that builds the immune system for the anti-tumor effects or treatment. Even though these limits might

appear unapparent a great approach for overcoming them has been presented as progress in tumor immunology and bioengineering that reawakened a very tenuous research area. Vaccines designed for the prevention or treatment of cancer differ greatly from the common vaccines which aim to protect new people from viruses or germs (as shown in Figure 7). They do not use the prophylactic method by protecting healthy cells and identifying sick ones but 'train' the immunities system to accustom itself to tumor cell identification and subsequent eradication. Cancer vaccination could be launched in several forms, such as vaccines. Some CAR-T cells express humanized antigens (proteins) while others prefer the expression of tumor tissue fragments. Simultaneously, methods can take the shape of personalized vaccines that are put to combat those patients who have mutations in tumors, which result in highly specific target vaccines(Fennemann et al., 2019). Cancer vaccine fundamentally aims to prime the body against cancer-associated targets and take the immune response as its goal. For those vaccines, adjuvants are part of the package that increases the immune response and directs it in a desired way, thus leading to efficiency. Geneticists are putting efforts into developing different types of vaccine delivery systems such as nanoparticles and specific virus-like structures to increase efficacy levels and the target immune cells are collected(Iyer et al., 2022).




Figure 7. Cancer Vaccine Stimulating the Immune System

Vaccine-associated mortality with cancer vaccines remains a longstanding myth in which the clinical trials of vaccination work sporadically. On one hand, cancer cells gaining the ability to escape immune system detection by an entirely new mechanism inspires the field with more and more questions and the models come out to explain the process of immune evasion. These cases include a co-treatment where cancer vaccines completely stop cancer which is superseded by the checkpoint inhibitors that just combine, they work together. It is additionally found that scientists are making vaccines that seek different cancer antigens simultaneously. This is, in a way, posing a challenge for the immune system to target these different antigens (Han et al., 2021). Oncolytic Viruses have been developed as a special type of virus or selected and modified whose job is to home and destroy cancer cells only (Lawler et al., 2017). They are a little two-faced in the sense that they can be pretty convincing at the moments when they are most talked about. The second one is that immunotherapy can induce one's immune system by blocking the effects of the body on the tumor cells. To start with, the tumor cells release cancer-pheromones as well as viral compounds due to their death. This together sends a signal to a large enough immune system to attack the dangerous processes within the cancer cells. Thus the oncolytic virus is fighting not only through the direct tumor-killing effect but is also able to overrule the tumor which is poor in immune cells till it turns it "hot" and activates immune cells (Lin et al., 2023).

The researches on oncolytic virotherapy are not limited only to one virus kind. Another famous example is the T-VEC virus which got its trial permission for use by the FDA in patients with advanced melanoma which was caused by the herpes simplex virus (Shalhout et al., 2023). The first era of oncolytic virus research was characterized by restricting factors with the actual targeting, modification, and adjusting of safety-enhancing features, and by now, these genetically modified viruses are optimized for the treatment of cancer. Another direction of research to be kept in mind is combinational therapy with concurrent use of oncolytic viruses along with other anticancer agents. The association of oncolytic viruses and checkpoint inhibitors may be a truly fruitful one, which would induce a more comprehensive immune response that the virus can only cause only (Martikainen & Essand, 2019). Another thing is that researchers are using these viruses as a source of oncolysis through which other therapeutic agents are directed toward the tumor. This is a multimodal way to exhibit anti-cancer effects by a single therapy. Two remarkable areas of cancer vaccine and oncolytic virus technologies are all now being spread out most exuberantly.

8. Future Directions and Challenges

What was the latest immunotherapy, for instance, is now not old yet compared to how quickly it has advanced in years. However, immunotherapy is an ever-changing profession. Overcoming resistance is paramount. This practice of medicine has shown the ability to stimulate very strong responses in selected cases, but not every immunotherapy is as effective and some individuals might not even respond to the treatment. Identifying patients in whom resistance will be more likely will, therefore, build the basis for coming up with corresponding schedules that could ensure a larger number of them derive the best from this treatment. One is how complex the cancer cell structures within the tumor are, the other is how complicated the tumor microenvironment is, and the other is the gut microbiome makeup (Nejman et al., 2020). To optimize effectiveness in the future, multi-directional tactics, rather than a one-way approach, are likely to be the standard. Combining several sorts of immunotherapies, for instance, administering checkpoint inhibitors in tandem with CAR-T cell therapy, or cancer vaccines is likely to stimulate more forceful treatment approaches (Marshall & Djamgoz, 2018). Alongside this, NLA-121 is still carried out for use with other traditional treatment modalities like chemotherapy and radiotherapy, which might improve their therapeutic efficiency. While this last option may have a few conditions with its usage which may cause side effects in the patients, saving their lives is still very important.

Identifying biomarkers that are not immunology-specific relies on a critical process. Right now, the options to determine the efficiency possibilities are rather limited that is, knowing which outcome is most likely in different treatments is very difficult. Similarly, the selection of suitable therapy types, relating to genetic testing of the cancer, immune system cell, or stomach microbiome markers, will be an approach for the doctors to make their decision in a personalized manner. As to the benefits of cancer treatment, it stands out in being so specific that it can be sharpened out to meet the best-matched dose including the stooping of the causes of wastage and expenses (Suri, 2022). One of the big issues to solve is how to expand the accessibility of immune therapy to the wider population. Nevertheless, cancers in the blood can be so remarkable that it still needs a lot to solve lymphoid ones on the other hand where the conversion of advantages to solid tumors is a research field that is pressing for now. Once next-generation CAR-T science emerges that focuses on striking strategic locations on oncolytic viruses, and also the latest vaccine designs are revealed it will possibly result in the invention of many modes of cancer treatment (Safarzadeh Kozani et al., 2022).

Another immunotherapeutic approach, instead of destroying and killing the body's invaders, can serve as a means of treating diseases such as cancer, besides autoimmune diseases because of its mode of action. The first successful and useful targeting therapy called “rheumatoid arthritis” that are helpful for various targeted antibody-based therapies has been the one to walk this way (Ferrari et al., 2015). The researchers now start the task of proportionally looking upon mechanisms of immune regulatory cells or switching the wayward immune response in autoimmune diseases and also they

have opened up the new potential to be tackled by tomorrow's therapy. Immunosuppressive therapy approach very soon might be substituted by advanced treatment methods and, therefore, they will be much less or detrimental in aspects of the sick side effects than their precedents (Abedon, 2019). The development of 'ready-made' solutions on the one hand in combination with a simplification in the production process along with a detailed investigation of whether the application of synthetic biology purposes may be used to reduce the level of the price and to increase the supply levels of these treatments that save people's lives should be done.

9. Conclusion

One is clear: immunotherapy is the newest approach to cancer, which is already being implemented now. Sometimes the things that fascinated scientists for years and were considered the most complicated phenomena of the immune system are the things that take the credit for the currently observed effects. Immune therapy changed the face of how cancer is treated radically and not just by paving the way for yet untapped promise for other diseases. Though problems persist around plagiarism, these technologies are very quickly improving. The fact is that immunotherapy is just in its infancy, and now we see the concept of the immune system of the highest level of complexity. As the tool, the direction of the future immunotherapy is being developed which is aimed to generate strong and specific therapies. Immunotherapy is, in consequence, the summation of progress in medical biology and of course, it gives the hope of writing the medicine's future.

References

- Abedon, S. T. (2019). Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. *Advanced Drug Delivery Reviews*, 145, 18-39.
- Afsahi, A. (2023). Augmentation of anti-myeloma engineered T cells by pharmacological or genetic interventions
- Ahmed, M. M. E. (2021). CAR-T cell therapy: current advances and future research possibilities. *Journal of Scientific Research in Medical and Biological Sciences*, 2(2), 86-116.
- Armstrong, V. (2015). Indonesian Day. *Vox Sanguinis*, 109(2), 1-96.
- Ayala, L. (2016). *Cybersecurity for hospitals and healthcare facilities*. Berkeley, CA.
- Bhatia, A., & Kumar, Y. (2014). Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. *Expert review of clinical immunology*, 10(1), 41-62.
- Bridge, J. A., Lee, J. C., Daud, A., Wells, J. W., & Bluestone, J. A. (2018). Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. *Frontiers in medicine*, 5, 351.
- Brüne, B., Dehne, N., Grossmann, N., Jung, M., Namgaladze, D., Schmid, T., von Knethen, A., & Weigert, A. (2013). Redox control of inflammation in macrophages. *Antioxidants & redox signaling*, 19(6), 595-637.
- Cauchon, N. S., Oghamian, S., Hassanpour, S., & Abernathy, M. (2019). Innovation in chemistry, manufacturing, and controls—a regulatory perspective from industry. *Journal of Pharmaceutical Sciences*, 108(7), 2207-2237.
- Chae, Y. K., Arya, A., Iams, W., Cruz, M. R., Chandra, S., Choi, J., & Giles, F. (2018). Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). *Journal for immunotherapy of cancer*, 6, 1-27.
- Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost,

- F., Reva, B., Lih, T.-S. M., & Chang, H.-Y. (2019). Integrated proteogenomic characterization of clear cell renal cell carcinoma. *Cell*, 179(4), 964-983. e931.
- Cobb, D. A., & Lee, D. W. (2021). Cytokine release syndrome biology and management. *The Cancer Journal*, 27(2), 119-125.
- Cole, K., Al-Kadhimi, Z., & Talmadge, J. E. (2023). Highlights into historical and current immune interventions for cancer. *International Immunopharmacology*, 117, 109882.
- Dey, A., Mitra, A., Pathak, S., Prasad, S., Zhang, A. S., Zhang, H., Sun, X.-F., & Banerjee, A. (2023). Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer. *Technology in Cancer Research & Treatment*, 22, 15330338231178403.
- Dobosz, P., & Dzieciatkowski, T. (2019). The intriguing history of cancer immunotherapy. *Frontiers in immunology*, 10, 496087.
- Falzone, L., Salomone, S., & Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. *Frontiers in Pharmacology*, 9, 421926.
- Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023). Therapeutic cancer vaccines: advancements, challenges, and prospects. *Signal Transduction and Targeted Therapy*, 8(1), 450.
- Fennemann, F. L., de Vries, I. J. M., Figdor, C. G., & Verdoes, M. (2019). Attacking tumors from all sides: personalized multiplex vaccines to tackle intratumor heterogeneity. *Frontiers in immunology*, 10, 454555.
- Ferrari, M., Onuoha, S. C., & Pitzalis, C. (2015). Trojan horses and guided missiles: targeted therapies in the war on arthritis. *Nature Reviews Rheumatology*, 11(6), 328-337.
- FIGLIN, R. A. (1999). Renal cell carcinoma: management of advanced disease. *The Journal of urology*, 161(2), 381-387.
- Flevaris, K., & Kontoravdi, C. (2022). Immunoglobulin G n-glycan biomarkers for autoimmune diseases: Current state and a glycoinformatics perspective. *International journal of molecular sciences*, 23(9), 5180.
- Fujii, T., Naing, A., Rolfo, C., & Hajjar, J. (2018). Biomarkers of response to immune checkpoint blockade in cancer treatment. *Critical reviews in oncology/hematology*, 130, 108-120.
- Garrison Jr, L. P., Neumann, P. J., Erickson, P., Marshall, D., & Mullins, C. D. (2007). Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. *Value in health*, 10(5), 326-335.
- Gupta, D., Bhattacharjee, O., Mandal, D., Sen, M. K., Dey, D., Dasgupta, A., Kazi, T. A., Gupta, R., Sinharoy, S., & Acharya, K. (2019). CRISPR-Cas9 system: A new-fangled dawn in gene editing. *Life sciences*, 232, 116636.
- Han, L., Peng, K., Qiu, L.-Y., Li, M., Ruan, J.-H., He, L.-L., & Yuan, Z.-X. (2021). Hitchhiking on controlled-release drug delivery systems: opportunities and challenges for cancer vaccines. *Frontiers in Pharmacology*, 12, 679602.
- Han, X. (2016). Engineering Chimeric Antigen Receptor T Cells towards Enhanced Safety and Efficacy in Cancer Immunotherapy [University of Southern California].
- Helmy, K. Y., Patel, S. A., Nahas, G. R., & Rameshwar, P. (2013). Cancer immunotherapy: accomplishments to date and future promise. *Therapeutic delivery*, 4(10), 1307-1320.
- Ikryannikova, L. N., Gorokhovets, N. V., Belykh, D. A., Kurbatov, L. K., & Zamyatnin Jr, A. A. (2023). Bacterial Therapy of Cancer: A Way to the Dustbin of History or to the Medicine of

the Future? *International journal of molecular sciences*, 24(11), 9726.

Iyer, S., Yadav, R., Agarwal, S., Tripathi, S., & Agarwal, R. (2022). Bioengineering strategies for developing vaccines against respiratory viral diseases. *Clinical microbiology reviews*, 35(1), e00123-00121.

Kamrani, A., Hosseinzadeh, R., Shomali, N., Heris, J. A., Shahabi, P., Mohammadinasab, R., Sadeghvand, S., Ghahremanzadeh, K., Sadeghi, M., & Akbari, M. (2023). New immunotherapeutic approaches for cancer treatment. *Pathology-Research and Practice*, 154632.

Kapoor-Narula, U., & Lenka, N. (2022). Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis. *Cytokine*, 157, 155968.

Kartikasari, A. E., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019). Therapeutic cancer vaccines—T cell responses and epigenetic modulation. *Frontiers in immunology*, 9, 429150.

Khan, A., & Lopez, M. (2023). Advances In Immunotherapy: A Comprehensive Review Of Medical Science. *The Research of Medical Science Review*, 1(01), 1-9.

Krzyszczczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., & Hartmanshenn, C. (2018). The growing role of precision and personalized medicine for cancer treatment. *Technology*, 6(03n04), 79-100.

Kumar, A. R., Devan, A. R., Nair, B., Vinod, B. S., & Nath, L. R. (2021). Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. *Molecular biology reports*, 1-21.

Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017). Oncolytic viruses in cancer treatment: a review. *JAMA oncology*, 3(6), 841-849.

Lazar, V., Ditu, L.-M., Pircalabioru, G. G., Gheorghe, I., Curutiu, C., Holban, A. M., Picu, A., Petcu, L., & Chifiriuc, M. C. (2018). Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. *Frontiers in immunology*, 9, 1830.

Lin, D., Shen, Y., & Liang, T. (2023). Oncolytic virotherapy: basic principles, recent advances and future directions. *Signal Transduction and Targeted Therapy*, 8(1), 156.

Liu, W. L., Zou, M. Z., Qin, S. Y., Cheng, Y. J., Ma, Y. H., Sun, Y. X., & Zhang, X. Z. (2020). Recent advances of cell membrane-coated nanomaterials for biomedical applications. *Advanced Functional Materials*, 30(39), 2003559.

Löwy, I. (2003). Immunotherapy of cancer from Coley's toxins to interferons: Molecularization of a therapeutic practice. *Molecularizing Biology and Medicine: New Practices and Alliances, 1920s to 1970s*, 233.

Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. *Journal of biomedical science*, 27, 1-30.

Manik, M., & Singh, R. K. (2022). Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. *Journal of medical virology*, 94(3), 869-877.

Marshall, H. T., & Djamgoz, M. B. (2018). Immuno-oncology: emerging targets and combination therapies. *Frontiers in oncology*, 8, 315.

Martikainen, M., & Essand, M. (2019). Virus-based immunotherapy of glioblastoma. *Cancers*, 11(2), 186.

- Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023). From bench to bedside: the history and progress of CAR T cell therapy. *Frontiers in immunology*, 14, 1188049.
- Mukherjee, B., Al Hoque, A., Chakraborty, A., Chakraborty, S., Dutta, L., Dutta, D., Banerjee, S., Dhara, M., & Deepa, R. M. (2022). Recent developments in cancer vaccines: where are we? *Nanotherapeutics in Cancer Vaccination and Challenges*, 29-75.
- Muszer, M., Noszczyńska, M., Kasperkiewicz, K., & Skurnik, M. (2015). Human microbiome: when a friend becomes an enemy. *Archivum immunologiae et therapiae experimentalis*, 63, 287-298.
- Nash, A., Aghlara-Fotovat, S., Hernandez, A., Scull, C., & Veisheh, O. (2021). Clinical translation of immunomodulatory therapeutics. *Advanced Drug Delivery Reviews*, 176, 113896.
- Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., & Gigi, E. (2020). The human tumor microbiome is composed of tumor type-specific intracellular bacteria. *Science*, 368(6494), 973-980.
- Neukart, F. (2024). Towards sustainable horizons: A comprehensive blueprint for Mars colonization. *Heliyon*.
- Nidhi, S., Anand, U., Oleksak, P., Tripathi, P., Lal, J. A., Thomas, G., Kuca, K., & Tripathi, V. (2021). Novel CRISPR-Cas systems: an updated review of the current achievements, applications, and future research perspectives. *International journal of molecular sciences*, 22(7), 3327.
- Pallister, C., & Watson, M. (2010). *Haematology*. Scion Publishing Ltd.
- Paul, W. E. (2012). *Fundamental immunology*. Lippincott Williams & Wilkins.
- Rahman, M. M., & McFadden, G. (2021). Oncolytic viruses: newest frontier for cancer immunotherapy. *Cancers*, 13(21), 5452.
- Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018). Oncolytic virus immunotherapy: future prospects for oncology. *Journal for immunotherapy of cancer*, 6, 1-13.
- Rapoport, B. L., van Eeden, R., Sibaud, V., Epstein, J. B., Klastersky, J., Aapro, M., & Moodley, D. (2017). Supportive care for patients undergoing immunotherapy. In: Springer.
- Romano, M. (2015). In vitro characterisation and expansion of human regulatory T cells for their in vivo application in the induction of tolerance in haematopoietic stem cell and solid organ transplantation.
- Roy, S., & Bagchi, B. (2020). Fluctuation theory of immune response: A statistical mechanical approach to understand pathogen induced T-cell population dynamics. *The Journal of Chemical Physics*, 153(4).
- Safarzadeh Kozani, P., Safarzadeh Kozani, P., Ahmadi Najafabadi, M., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022). Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? *Frontiers in immunology*, 13, 795164.
- Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023). Therapy with oncolytic viruses: progress and challenges. *Nature Reviews Clinical Oncology*, 20(3), 160-177.
- Shouval, R., Alarcon Tomas, A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., Olaide Afuye, A., Alperovich, A., Anagnostou, T., & Besser, M. J. (2022). Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. *Journal of clinical oncology*, 40(4), 369-381.
- Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C., Marques, M. A., Ferretti, G. D., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. (2023). Targeting biomolecular condensation and protein

aggregation against cancer. *Chemical Reviews*, 123(14), 9094-9138.

Šmardová, J. (2024). What tumors teach us: Parallels in cell and human behavior (Vol. 2). Masarykova univerzita.

Sompayrac, L. M. (2022). How the immune system works. John Wiley & Sons.

Srivastava, S. R., Ramana, J., & Lahmo, P. (2019). T-Cell Immunotherapies Market 4th Edition 2019-2030.

Suri, V. K. (2022). Functional Automation and Digital Transformation. Dorrance Publishing.

Suryaprakash, R. T. C., Safi, M. A. A., Alonazi, N., Alsieedi, A. A., & Kujan, O. (2023). Immunotherapy and Cancer Stem Cells. *Molecular Targets and Cancer Therapeutics (Part 2)*, 165.

Tian, Y., Xie, D., & Yang, L. (2022). Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. *Signal Transduction and Targeted Therapy*, 7(1), 117.

Ventola, C. L. (2017). Cancer immunotherapy, part 1: current strategies and agents. *Pharmacy and therapeutics*, 42(6), 375.

Wilky, B. A. (2019). Immune checkpoint inhibitors: The linchpins of modern immunotherapy. *Immunological reviews*, 290(1), 6-23.

Willcox, C. R., Mohammed, F., & Willcox, B. E. (2020). The distinct MHC-unrestricted immunobiology of innate-like and adaptive-like human $\gamma\delta$ T cell subsets—Nature's CAR-T cells. *Immunological reviews*, 298(1), 25-46.

Williams, C. K. O., & Williams, C. K. O. (2019). Historical Perspectives. *Cancer and AIDS: Part I: An Historical Perspective*, 15-59.

Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021). Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. *Cancer and Metastasis Reviews*, 40, 949-982.

Wu, C., Wang, A. C., Ding, W., Guo, H., & Wang, Z. L. (2019). Triboelectric nanogenerator: a foundation of the energy for the new era. *Advanced Energy Materials*, 9(1), 1802906.

Zhang, T., Kurban, E., & Wang, Z. (2023). Neoantigens: The Novel Precision Cancer Immunotherapy. *Biologics*, 3(4), 321-334.

About The Authors

Maria Nazir is an MPhil Scholar of Microbiology at the Cholistan University of Veterinary and Animal Sciences (CUVAS) in Bahawalpur, Pakistan. She is involved in a National Research Program for Universities (NRPU) Project, with research interests in Molecular Characterization. She has submitted abstracts to various conferences and authored and coauthored of several book chapters. Her research focuses on the isolation and Molecular characterization of *Corynebacterium pseudotuberculosis* and their applications in promoting animal health. Her interested research criteria are based on genetics, molecular biology, and bioinformatics.

Email: nazirmaria545@gmail.com

ORCID 0009-0004-6714-6212

Aansa Tahreem earned a Bachelor's in applied microbiology from the Cholistan University of Veterinary and Animal Sciences (CUVAS) in Bahawalpur Pakistan. Currently, she is doing an M. Phil in Microbiology from the University of Veterinary and Animal Sciences (UVAS) in Lahore Pakistan. Her research interests are in Microbial genetics, Molecular biology, soil microbiology, plant Microbiology, and food quality and its application. She has a single publication in international journals.

E-mail: aansa45tehreem@gmail.com

ORCID: 0009-0001-6208-8090

Dr. Rumaisa Nawal received her MBBS degree in 2024 from Multan Medical and dental college. She is a house officer in Bhawal Victoria Hospital, Pakistan. She has done internship program at District Headquarters Lodhran.

Email: rumaisanawal9@gmail.com

ORCID:0009-0000-1903-8365

Ms. Fatima Sagheer doing MPhil in Biotechnology at The Islamia University of Bahawalpur. Her research interests include Bioremediation & Biotransformation of environmental Contaminants using microbes.

Email: fatimasagheer336@gmail.com

ORCID: 0009-0002-8381-1089

Shafeeq Ur Rehman earned his Bachelor in Applied microbiology from Cholistan University of Veterinary and Animal Sciences (CUVAS) Bahawalpur Pakistan. Currently he is pursuing M. phil in Microbiology from Cholistan University of Veterinary and Animal Sciences (CUVAS) Bahawalpur Pakistan. He is also working as research assistant in a project titled as “Robust Molecular Detection of Silent Circulation of FMD and PPR Viruses in Cholistan as a Model for Disease-Free Zone”. His research interest is in FMD and PPR Viruses, Mucosal Immunity, Virology, Molecular cell biology, Cell culture, Microbial genetics and CRISPR case tools for combating viral diseases. He has published 7 articles and many book chapters in national and international journals.

Email: shafeequrrehmanbhutta@gmail.com

ORCID: 0000-0003-3571-8226

Dr. Muhammad SAFDAR earned his PhD in Molecular Biology and Genetics from Gaziantep University, Turkey. He is Lecturer in the Breeding and Genetics department at Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, Pakistan. His research interests are molecular genetics and genomics, nutrigenomics, nano-genomics, bioinformatics, biotechnology, and their applications. He has published more than 70 research articles in national and international journals. He has also written many book chapters as well as an edited book. He is an associate editor for international journals.

E-mail: msafdar@cuvas.edu.pk

ORCID: 0000 0002 3720 2090

Prof. Dr. Mehmet ÖZASLAN received his PhD in 1995 Institute of Natural Sciences at Cukurova University, Turkiye. He is a Professor in Molecular Biology and Genetics. His research interests are included Cancer Genetics, Molecular Virology, Molecular Genetics, Microbiology, and Genetic mutations etc. He has published more than 200 research articles in national and international well reputed journals. He also has written many book chapters as well as edited books. He is an editor and editor-in-chief of many well-reputed national and international journals.

E-mail: ozaslanmd@gantep.edu.tr,

ORCID: 0000 0001 9380 4902

To Cite This Chapter

NAZIR M et al., (2024). Rebooting the body's defense: innovations in immunotherapy treatment. In *Current Studies in Health and Life Sciences 2024* (pp.145-162). ISRES Publishing.